CoChat
Sign Up
Cited by 237Monoclonal and Polyclonal Antibodies ResearchRadiopharmaceutical Chemistry and ApplicationsNanoparticle-Based Drug Delivery

Affinity and Avidity in Antibody-Based Tumor Targeting

Open access
Rudnick, Stephen I., Adams, Gregory P.·2009·Cancer Biotherapy and Radiopharmaceuticals
DOI 10.1089/cbr.2009.0627PMC PMC2902227
Open this paper in CoChat — free account

Abstract

Many factors contribute to successful tumor targeting by antibodies. Besides properties of the tumor tissue and general antibody pharmacology, a relationship exists between an antibody and its antigen that can shape penetration, catabolism, specificity, and efficacy. The affinity and avidity of the binding interactions play critical roles in these dynamics. In this work, we review the principles that guide models predicting tumor penetration and cellular internalization while providing a critical overview of studies aimed at experimentally determining the specific role of affinity and avidity in these processes. One should gain the perspective that binding affinity can, in part, dictate the localization of antibodies in tumors, leading to high concentrations in the perivascular space or low concentrations diffused throughout the tumor. These patterns can be simply due to the diminution of available dose by binding antigen and are complicated by internalization and degradation stemming from slow rates of dissociation. As opposed to the trend of simply increasing affinity to increase efficacy, novel strategies that increase avidity and broaden specificity have made significant progress in tumor targeting.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/cbr.2009.0627

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Factors influencing mAbs distribution to individual organs or tissues include drug-specific features such as binding affinity to target antigens, target internalization rate, mAb hydrophilicity, and charge, and tissue-specific features such as membrane structure and blood flow.

    “Additional factors influencing mAbs distribution to individual organs or tissues include: drug‐specific features such as their binding affinity to specific target antigens, targets internalization rate,24 mAb hydrophilicity, charge,25 and tissue‐specific features such as membrane structure and blood flow.26”

    From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [24]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Rudnick, S. I., & Adams, G. P.
Affiliations
Fox Chase Cancer Center (US)
Corresponding author
Adams, Gregory P.
ORCID
Adams, Gregory P.
Venue
Cancer Biotherapy and Radiopharmaceuticals
Publisher
SAGE Publications
Published
2009-04
Volume
24
Issue
2
Pages
155-161
ISSN
  • 1084-9785 (ISSN-L)
  • 1557-8852
DOI
10.1089/cbr.2009.0627
PMC
PMC2902227
OpenAlex
W2083764503
Cited by
237
References
49
Citations by year
2026: 8 · 2025: 9 · 2024: 14 · 2023: 13 · 2022: 13 · 2021: 22 · 2020: 12 · 2019: 14 · 2018: 25 · 2017: 10 · 2016: 19 · 2015: 16 · 2014: 10 · 2013: 15 · 2012: 19
FWCI
9.04
Type
journal article
Language
en
Open access
Licence
www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
Locations
  • Cancer Biotherapy and Radiopharmaceuticals (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (R01CA118159)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
antibody affinity, avidity, tumor targeting, antibody-antigen binding, tumor penetration, antibody internalization, antibody dissociation, perivascular spaces, antibody pharmacokinetics, antibody specificity, antibody catabolism
MeSH terms
Animals, Antibodies, Monoclonal, Antibody Affinity, Antibody Specificity, Antigens, Neoplasm, Humans, Immunoglobulin Fragments, Neoplasms, Immunoconjugates, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review